Holen Sie sich die Stockscreener-App
110.13
1.41%
-1.57
Handel nachbörslich:
110.13
Schlusskurs vom Vortag:
$111.70
Offen:
$111.44
24-Stunden-Volumen:
1.66M
Relative Volume:
0.71
Marktkapitalisierung:
$219.89B
Einnahmen:
$53.22B
Nettoeinkommen (Verlust:
$12.86B
KGV:
17.23
EPS:
6.39
Netto-Cashflow:
$14.85B
1W Leistung:
-1.08%
1M Leistung:
+8.01%
6M Leistung:
+3.46%
1J Leistung:
+10.57%
1-Tages-Spanne:
$109.77
$111.44
1-Wochen-Bereich:
$109.77
$114.88
52-Wochen-Spanne:
$96.06
$120.92
Novartis Ag Adr Stock (NVS) Company Profile
Vergleichen Sie NVS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NVS
Novartis Ag Adr
|
110.13 | 219.89B | 53.22B | 12.86B | 14.85B | 6.39 |
|
LLY
Lilly Eli Co
|
751.45 | 681.85B | 49.00B | 11.11B | -1.27B | 12.29 |
|
JNJ
Johnson Johnson
|
155.66 | 370.90B | 89.33B | 21.81B | 18.57B | 8.99 |
|
ABBV
Abbvie Inc
|
185.58 | 342.01B | 57.37B | 4.20B | 17.83B | 2.35 |
|
NVO
Novo Nordisk Adr
|
64.85 | 291.20B | 42.09B | 14.65B | 10.11B | 3.2833 |
Novartis Ag Adr Stock (NVS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-13 | Herabstufung | UBS | Buy → Neutral |
| 2025-02-12 | Eingeleitet | Morgan Stanley | Underweight |
| 2025-02-04 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2024-12-04 | Herabstufung | HSBC Securities | Hold → Reduce |
| 2024-09-11 | Herabstufung | BofA Securities | Buy → Neutral |
| 2024-09-05 | Herabstufung | Goldman | Buy → Neutral |
| 2024-09-03 | Herabstufung | Jefferies | Buy → Hold |
| 2024-07-19 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2024-05-30 | Eingeleitet | Goldman | Buy |
| 2024-02-23 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2024-01-23 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2024-01-16 | Fortgesetzt | UBS | Buy |
| 2023-12-18 | Herabstufung | HSBC Securities | Buy → Hold |
| 2023-09-25 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-04-26 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2023-03-27 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2023-01-26 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-12-05 | Hochstufung | Stifel | Hold → Buy |
| 2022-09-15 | Herabstufung | Credit Suisse | Neutral → Underperform |
| 2022-09-14 | Herabstufung | Berenberg | Buy → Hold |
| 2022-05-09 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2022-01-10 | Fortgesetzt | Citigroup | Buy |
| 2021-12-14 | Herabstufung | Redburn | Buy → Neutral |
| 2021-12-06 | Herabstufung | Exane BNP Paribas | Outperform → Neutral |
| 2021-12-03 | Herabstufung | Bryan Garnier | Buy → Neutral |
| 2021-09-20 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2021-03-22 | Eingeleitet | Bernstein | Mkt Perform |
| 2021-03-10 | Herabstufung | Argus | Buy → Hold |
| 2021-02-01 | Herabstufung | Cowen | Outperform → Market Perform |
| 2021-01-15 | Eingeleitet | Deutsche Bank | Buy |
| 2020-09-29 | Eingeleitet | Berenberg | Buy |
| 2020-09-10 | Hochstufung | UBS | Neutral → Buy |
| 2020-09-01 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-06-15 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-03-10 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2020-02-25 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-04-25 | Hochstufung | Guggenheim | Neutral → Buy |
| 2019-04-25 | Hochstufung | Liberum | Hold → Buy |
| 2019-04-10 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2019-01-02 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2018-12-11 | Fortgesetzt | Jefferies | Buy |
| 2018-10-09 | Eingeleitet | Guggenheim | Neutral |
| 2018-09-10 | Hochstufung | BofA/Merrill | Underperform → Buy |
| 2018-05-29 | Herabstufung | HSBC Securities | Buy → Hold |
| 2018-05-25 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2018-01-25 | Bestätigt | Leerink Partners | Outperform |
| 2017-12-06 | Herabstufung | BofA/Merrill | Neutral → Underperform |
| 2017-07-26 | Hochstufung | Morgan Stanley | Underweight → Overweight |
| 2017-07-05 | Herabstufung | Credit Suisse | Neutral → Underperform |
| 2017-03-09 | Eingeleitet | Liberum | Buy |
Alle ansehen
Novartis Ag Adr Aktie (NVS) Neueste Nachrichten
Contract Research and Manufacturing Services (CRAMS) Business Report 2025: Market to Reach $211.4 Billion by 2030, Fueled by Growing Demand for Biologics and Biosimilars - GlobeNewswire Inc.
NVS’s Stock Market Odyssey: A Year of Growth, Decline, and Resilience - investchronicle.com
Novartis Earnings: Strong First-Quarter Supports Increased Full-Year Guidance - Morningstar
Novartis ADR earnings beat by $0.20, revenue topped estimates - Investing.com
Novartis Holds a Strong Branded Drug Portfolio Supporting Steady Long-Term Growth - Morningstar
Novartis Beats On Q1 Earnings And Sales, Raises Guidance, Stock Up - Barchart.com
Roche to invest US$50-billion in U.S. to avoid Trump tariffs, create 12,000 jobs - The Globe and Mail
Novartis to Report Q1 Earnings: Will Key Drugs Maintain Momentum? - Yahoo Finance
Swiss pharmaceutical giant announces plans for $1.1B campus in San Diego - fox5sandiego.com
Stocks to Watch Friday: JPMorgan, Wells Fargo, BlackRock, Newmont - WSJ
Pharma Stock Roundup: FDA Nod To SNY, AZN & NVS, JNJ Talc Suits Failure - Barchart.com
FDA Grants Accelerated Approval To NVS Kidney Disease Drug - Barchart.com
Quantum Corp’s Banking’s 100-Day Moving Average at 21.57: Will the Stock Break Through? - investchronicle.com
No room on the ARK? - Morningstar
5 Large Drug Stocks To Watch As Industry Recovers - Barchart
FDA Approves Novartis Drug For Rare Kidney Disease Treatment - Barchart
Novartis scraps use of diverse panels for hires in US - Reuters
Alnylam Rallies 62% In A Year: Can The Stock Maintain This Momentum? - Barchart
Bioengineered Protein Drugs Market Size to Cross USD 672.7 Billion by 2034, Growing at a CAGR of 6.2% - GlobeNewswire Inc.
Complement C4 Antibody Market Research 2025: Growing Focus on Precision Medicine and Targeted Therapies, and Increasing Investment in Immunotherapies and Biologic Drugs - GlobeNewswire Inc.
Alberta sets a new standard for advanced prostate cancer treatment with public reimbursement of Pluvicto™ - Barchart
Giovanni Caforio, M.D. - Novartis
Novartis Near Buy Point; Earns Near-Best Overall Rating - Investor's Business Daily
META_TITLE_QUOTE - Yahoo Finance
Novartis Earnings Surprised The Street; Still Going Strong - Investor's Business Daily
Novartis Gets CHMP Opinion for Label Expansion of Fabhalta - Yahoo Finance
AZN: 3 AI-Powered Drug Discovery Stocks Revolutionizing Medicine - StockNews.com
Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace
NVS: 3 Gene Therapy Stocks With Game-Changing Potential - StockNews.com
NVS Quantitative Stock Analysis - Nasdaq
Novartis: Strong Execution With A P/E Discount (NYSE:NVS) - Seeking Alpha
Company’s Banking Stock: Dissecting a 2.21% Quarterly Revenue Decline Amid Growth - The InvestChronicle
Finanzdaten der Novartis Ag Adr-Aktie (NVS)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.86%
0.79%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):